JP7422480B2 - 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質 - Google Patents

制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質 Download PDF

Info

Publication number
JP7422480B2
JP7422480B2 JP2017553119A JP2017553119A JP7422480B2 JP 7422480 B2 JP7422480 B2 JP 7422480B2 JP 2017553119 A JP2017553119 A JP 2017553119A JP 2017553119 A JP2017553119 A JP 2017553119A JP 7422480 B2 JP7422480 B2 JP 7422480B2
Authority
JP
Japan
Prior art keywords
cells
mutein
human
protein
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017553119A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018512151A (ja
JP2018512151A5 (enExample
Inventor
バッツ，エリック・アラン
トムソン，クリスティ・アン
ギャビン，マルク・アラン
フォルツ，イアン・ネビン
シア，ドン
アルコーン，ディナ・エヌ
リム，アイ・チン
ケッチェム，ランドル・ロバート
マンチュレンコ，キャシー
セキロフ，ローラ
ベリー，ケリー・アン
デ・イムス，シール・クロビス・チュア
アグラワル，ニーラジ・ジャグディシュ
カナン，グナセーカラン
リー，リー
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2018512151A publication Critical patent/JP2018512151A/ja
Publication of JP2018512151A5 publication Critical patent/JP2018512151A5/ja
Priority to JP2021096449A priority Critical patent/JP2021153593A/ja
Priority to JP2023106755A priority patent/JP7649349B2/ja
Application granted granted Critical
Publication of JP7422480B2 publication Critical patent/JP7422480B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
JP2017553119A 2016-05-04 2016-05-04 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質 Active JP7422480B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021096449A JP2021153593A (ja) 2016-05-04 2021-06-09 制御性ｔ細胞の増殖のためのインターロイキン−２変異タンパク質
JP2023106755A JP7649349B2 (ja) 2016-05-04 2023-06-29 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2016/030843 WO2016164937A2 (en) 2015-04-10 2016-05-04 Interleukin-2 muteins for the expansion of t-regulatory cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021096449A Division JP2021153593A (ja) 2016-05-04 2021-06-09 制御性ｔ細胞の増殖のためのインターロイキン−２変異タンパク質

Publications (3)

Publication Number Publication Date
JP2018512151A JP2018512151A (ja) 2018-05-17
JP2018512151A5 JP2018512151A5 (enExample) 2019-06-06
JP7422480B2 true JP7422480B2 (ja) 2024-01-26

Family

ID=61598336

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017553119A Active JP7422480B2 (ja) 2016-05-04 2016-05-04 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質
JP2021096449A Pending JP2021153593A (ja) 2016-05-04 2021-06-09 制御性ｔ細胞の増殖のためのインターロイキン−２変異タンパク質
JP2023106755A Active JP7649349B2 (ja) 2016-05-04 2023-06-29 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021096449A Pending JP2021153593A (ja) 2016-05-04 2021-06-09 制御性ｔ細胞の増殖のためのインターロイキン−２変異タンパク質
JP2023106755A Active JP7649349B2 (ja) 2016-05-04 2023-06-29 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質

Country Status (6)

Country Link
EP (2) EP3280725B1 (enExample)
JP (3) JP7422480B2 (enExample)
KR (3) KR20250133490A (enExample)
CN (2) CN115073581A (enExample)
NZ (1) NZ775714A (enExample)
WO (1) WO2016164937A2 (enExample)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10048271B2 (en) 2012-12-11 2018-08-14 Albert Einstein College Of Medicine, Inc. Methods for high throughput receptor:ligand identification
WO2016100375A2 (en) * 2014-12-15 2016-06-23 Washington University Compositions and methods for targeted cytokine delivery
KR102739782B1 (ko) * 2015-09-11 2024-12-09 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 생물학적으로 관련된 직교 사이토카인/수용체 쌍
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
WO2017136818A2 (en) 2016-02-05 2017-08-10 Washington University Compositions and methods for targeted cytokine delivery
US11505591B2 (en) 2016-05-18 2022-11-22 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
AU2017266905B2 (en) 2016-05-18 2022-12-15 Albert Einstein College Of Medicine, Inc. Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
WO2017220704A1 (en) 2016-06-22 2017-12-28 David Klatzmann Genetically modified t lymphocytes
SG11201903882VA (en) * 2016-11-08 2019-05-30 Delinia Inc Il-2 variants for the treatment of autoimmune diseases
KR102760578B1 (ko) 2016-12-22 2025-02-03 큐 바이오파마, 인크. T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
IL269000B2 (en) 2017-03-15 2024-06-01 Cue Biopharma Inc Methods for modulating an immune response
JP7165717B2 (ja) 2017-03-15 2022-11-04 パンディオン・オペレーションズ・インコーポレイテッド 標的免疫寛容
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
KR20250145137A (ko) * 2017-08-03 2025-10-13 신톡스, 인크. 자가면역 질환의 치료를 위한 사이토카인 접합체
EP3678677A4 (en) * 2017-09-07 2021-06-16 Cue Biopharma, Inc. Antigen-presenting polypeptides and methods of use thereof
TW201920249A (zh) * 2017-09-07 2019-06-01 美商信號生物製藥公司 具有結合位點之t細胞調節多聚體多肽及其使用方法
JP2021505156A (ja) * 2017-12-06 2021-02-18 パンディオン・オペレーションズ・インコーポレイテッド 標的化免疫寛容
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
BR112020011343A2 (pt) * 2017-12-06 2020-11-17 Pandion Therapeutics, Inc. muteínas de il-2 e seus usos
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
JP7275049B2 (ja) * 2017-12-27 2023-05-17 協和キリン株式会社 Ｉｌ－２改変体
CN111886241A (zh) 2018-01-09 2020-11-03 库尔生物制药有限公司 多聚体t细胞调节多肽及其使用方法
WO2020113403A1 (en) * 2018-12-04 2020-06-11 Beijing Percans Oncology Co. Ltd. Cytokine fusion proteins
CN112105632A (zh) 2018-01-24 2020-12-18 北京智康博药肿瘤医学研究有限公司 细胞因子融合蛋白
WO2019158764A1 (en) 2018-02-16 2019-08-22 Iltoo Pharma Use of interleukin 2 for treating sjögren's syndrome
KR102824112B1 (ko) * 2018-03-28 2025-06-24 브리스톨-마이어스 스큅 컴퍼니 인터루킨-2/인터루킨-2 수용체 알파 융합 단백질 및 사용 방법
AU2019288496B2 (en) * 2018-06-22 2024-11-21 Cugene Inc. Interleukin-2 variants and methods of uses thereof
CN113038964B (zh) * 2018-06-29 2025-05-27 德克拉有限公司 超长效胰岛素-fc融合蛋白及使用方法
WO2020007937A1 (en) 2018-07-03 2020-01-09 Iltoo Pharma Use of interleukin-2 for treating systemic sclerosis
WO2020035482A1 (en) 2018-08-13 2020-02-20 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
PL3715367T3 (pl) 2018-09-17 2024-09-02 Gi Innovation, Inc. Białko fuzyjne zawierające białko il-2 i białko cd80 oraz jego zastosowanie
BR112021005401A2 (pt) 2018-11-08 2021-06-29 Synthorx, Inc. conjugados de interleucina 10 e usos dos mesmos
WO2020132368A1 (en) * 2018-12-19 2020-06-25 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
EP3901167A4 (en) * 2018-12-21 2022-11-16 Hanmi Pharm. Co., Ltd. NOVEL IMMUNOSUPRESSIVE INTERLEUKIN 2
MX2021008147A (es) * 2019-01-07 2021-08-11 Inhibrx Inc Polipeptidos que comprenden polipeptidos con il-2 modificada y usos de los mismos.
US20200246467A1 (en) 2019-02-06 2020-08-06 Synthorx, Inc. Il-2 conjugates and methods of use thereof
MA54955A (fr) 2019-02-15 2021-12-22 Integral Molecular Inc Anticorps anti-claudine 6 et leurs utilisations
US11254736B2 (en) 2019-02-15 2022-02-22 Integral Molecular, Inc. Antibodies comprising a common light chain and uses thereof
CA3141327A1 (en) 2019-05-20 2020-11-26 Pandion Operations, Inc. Madcam targeted immunotolerance
AU2020282736B2 (en) * 2019-05-29 2025-10-30 Cue Biopharma, Inc. Multimeric T-cell modulatory polypeptides and methods of use thereof
US20220235109A1 (en) * 2019-06-14 2022-07-28 Cugene Inc Novel interleukin-2 variants for the treatment of cancer
PH12022550165A1 (en) 2019-07-26 2023-05-08 Visterra Inc Interleukin-2 agents and uses thereof
UY38836A (es) * 2019-08-13 2021-02-26 Amgen Inc Muteínas de interleucina-2 para la expansión de células t reguladoras
KR20220044834A (ko) * 2019-08-15 2022-04-11 사이팀 테라퓨틱스, 인크. 변형된 인터루킨 2 (il-2) 폴리펩타이드, 컨쥬게이트 및 이의 용도
PH12022500004A1 (en) 2019-08-23 2023-04-03 Synthorx Inc Il-15 conjugates and uses thereof
MX2022002740A (es) 2019-09-10 2022-03-25 Synthorx Inc Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes.
CN110642934B (zh) * 2019-09-10 2022-08-23 中国医学科学院北京协和医院 靶向调节t细胞的长效白介素-2及其在治疗自身免疫病中的应用
AU2020383176B2 (en) * 2019-11-15 2023-10-19 Genexine, Inc. Fusion protein including modified interleukin-7 and TGF beta receptor II and use thereof
EP4061837A1 (en) 2019-11-18 2022-09-28 Janssen Biotech, Inc. Anti-cd79 chimeric antigen receptors, car-t cells, and uses thereof
WO2021102063A1 (en) 2019-11-20 2021-05-27 Anwita Biosciences, Inc. Cytokine fusion proteins, and their pharmaceutical compositions and therapeutic applications
BR112022011414A2 (pt) 2019-12-12 2022-08-30 Iltoo Pharma Construção quimérica, proteína homodimérica, proteína heterodimérica, ácido nucleico, vetor, célula hospedeira, métodos para produzir uma proteína dimérica e para produzir uma proteína heterodimérica
CA3155759A1 (en) * 2019-12-13 2021-06-17 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anti-tslp antibody and uses thereof
CN114867749A (zh) * 2019-12-17 2022-08-05 安进公司 用于疗法中的双重白介素-2/tnf受体激动剂
IL293978A (en) 2019-12-20 2022-08-01 Regeneron Pharma New il2 agonists and methods of using them
JP2023514010A (ja) 2020-01-10 2023-04-05 ブライト ピーク セラピューティクス エージー 修飾ｉｌ－２ポリペプチドおよびその使用
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
KR20220143869A (ko) * 2020-02-21 2022-10-25 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 항-il-2 항체, 이의 항원-결합 단편 및 이의 의학적 용도
US20230090069A1 (en) 2020-03-06 2023-03-23 Centre Hospitalier Universitaire De Nimes Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis
IL295826B2 (en) * 2020-03-31 2025-11-01 Hanmi Pharmaceutical Co Ltd Novel immunostimulating il-2 analogs
WO2021216488A1 (en) 2020-04-21 2021-10-28 Regeneron Pharmaceuticals, Inc. Il-2 variants with reduced binding to il-2 receptor alpha and uses thereof
WO2021222150A2 (en) * 2020-04-28 2021-11-04 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
WO2021231376A2 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
MX2022016532A (es) * 2020-07-02 2023-04-12 Inhibrx Inc Polipeptidos que comprenden polipeptidos de il-2 modificados y usos de los mismos.
CN116113428A (zh) * 2020-09-01 2023-05-12 武田药品工业株式会社 白细胞介素-2突变蛋白及其用途
CN116323653A (zh) * 2020-09-04 2023-06-23 山东先声生物制药有限公司 Il-2突变体及其应用
EP4211149A4 (en) 2020-09-09 2024-10-09 Cue Biopharma, Inc. MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF
US12024559B2 (en) 2020-10-23 2024-07-02 Asher Biotherapeutics, Inc. Fusions with CD8 antigen binding molecules for modulating immune cell function
MX2023005030A (es) 2020-10-29 2023-05-16 Bristol Myers Squibb Co Proteinas de fusion para el tratamiento de enfermedades.
AU2021391924A1 (en) 2020-12-04 2023-06-22 The General Hospital Corporation Methods of using interleukin-2 agents
AU2022211021A1 (en) 2021-01-20 2023-08-03 Visterra, Inc. Interleukin-2 mutants and uses thereof
IL304365B2 (en) * 2021-03-31 2025-04-01 Hanmi Pharmaceutical Co Ltd A novel conjugate of an IL2 immunostimulatory analog and method of preparation thereof
EP4323392A4 (en) * 2021-04-16 2025-03-19 Orionis Biosciences, Inc. IL-2-BASED CONSTRUCTS
TW202317623A (zh) 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法
WO2023004004A1 (en) * 2021-07-23 2023-01-26 Merck Sharp & Dohme Llc Il-2 muteins for treating cancer or infection
CN113831402A (zh) * 2021-07-30 2021-12-24 西安龙腾景云生物科技有限公司 一种人白细胞介素2变体及其用途
JP2024536840A (ja) * 2021-09-26 2024-10-08 ウーシー バイオロジクス アイルランド リミテッド Ｉｌ－２バリアント及びその融合タンパク質
US20240376172A1 (en) 2021-10-06 2024-11-14 Iltoo Pharma Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues
CN120131911A (zh) 2021-12-01 2025-06-13 威特拉公司 使用白细胞介素-2药剂的方法
CN114349843B (zh) * 2022-01-18 2024-05-14 浙江博锐生物制药有限公司 白细胞介素-2衍生物及其制备方法和应用
US20250186550A1 (en) * 2022-03-03 2025-06-12 Hainan Simcere Pharmaceutical Co., Ltd. Pharmaceutical composition of il2 mutant-antibody fc block fusion protein and use thereof
IL317511A (en) 2022-06-16 2025-02-01 Cephalon Llc IL-2 immunoconjugates attenuated by anti-PD-1 antibody and their uses
US20260092095A1 (en) 2022-09-12 2026-04-02 Inserm (Institut National De La Santé Et La Recherche Médicale) Interleukin-2 for use in treating autism spectrum disorder
CN118056840A (zh) * 2022-11-18 2024-05-21 南京诺艾新生物技术有限公司 受体亲和力偏好性的定点偶联聚乙二醇化白介素-2突变体及其用途
EP4626933A1 (en) 2022-11-30 2025-10-08 Integral Molecular, Inc. Antibodies directed to claudin 6, including bispecific formats thereof
WO2024121173A1 (en) 2022-12-05 2024-06-13 Centre Hospitalier Universitaire De Nimes Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis in a subgroup of patients
CN120529914A (zh) 2023-01-09 2025-08-22 奥德赛治疗股份有限公司 抗tnfr2抗原结合蛋白及其用途
TW202602941A (zh) 2024-04-10 2026-01-16 美商奧迪希治療公司 抗tnfr2抗原結合蛋白及其用途
US20260028384A1 (en) 2024-04-17 2026-01-29 Visterra, Inc. Use of il-2 variant for treating kidney transplant rejection
WO2026006809A1 (en) 2024-06-27 2026-01-02 Odyssey Therapeutics, Inc. Multispecific molecules binding tnfr2 and cd25 and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011519882A (ja) 2008-05-08 2011-07-14 アイクリス ゲーエムベーハー ウント コー．カーゲー 自己免疫疾患の治療および／または予防のための薬剤、ならびに制御性ｔ細胞形成のための薬剤
WO2014153111A2 (en) 2013-03-14 2014-09-25 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US6239328B1 (en) 1992-10-05 2001-05-29 North Carolina State University Method for reducing expression variability of transgenes in plant cells
US6037525A (en) 1996-08-01 2000-03-14 North Carolina State University Method for reducing expression variability of transgenes in plant cells
US6245974B1 (en) 1997-08-06 2001-06-12 North Carolina State University Matrix attachment regions
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
US6177612B1 (en) 1998-07-31 2001-01-23 Her Majesty The Queen In Right Of Canada, As Represented By The Department Of Agriculture And Agri-Food Canada Matrix attachment regions
US6388066B1 (en) 1998-09-29 2002-05-14 Pioneer Hi-Bred International, Inc. MAR/SAR elements flanking RSYN7-driven construct
KR100408844B1 (ko) 2000-07-29 2003-12-06 한국산업기술평가원 동물세포 발현벡터
WO2002048379A1 (en) 2000-12-15 2002-06-20 Pangen Biotech Inc. Expression vector for animal cell containing nuclear matrix attachment region fo interferon beta
EP1395669B1 (en) 2001-01-26 2009-07-22 Selexis S.A. Matrix attachment regions and methods for use thereof
ATE542137T1 (de) 2001-12-04 2012-02-15 Merck Patent Gmbh Immunocytokine mit modulierter selektivität
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
ATE514783T1 (de) 2003-11-12 2011-07-15 Schering Corp Plasmidsystem zur expression mehrerer gene
EP1723251A4 (en) * 2004-03-05 2008-04-23 Novartis Vaccines & Diagnostic IN VITRO TEST SYSTEM FOR THE FORECASTING THE COMPATIBILITY OF A PATIENT AGAINST THERAPEUTICS
US20060069515A1 (en) * 2004-09-30 2006-03-30 International Business Machines Corporation Method and system for protein folding trajectory analysis using patterned clusters
WO2006138181A2 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
US7695963B2 (en) 2007-09-24 2010-04-13 Cythera, Inc. Methods for increasing definitive endoderm production
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
US20110274650A1 (en) * 2009-01-21 2011-11-10 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
MX340971B (es) 2009-11-23 2016-08-02 Amgen Inc * Fragmento cristalizable (fc) de anticuerpo monomerico.
HK1220376A1 (zh) 2013-03-15 2017-05-05 Angelica Therapeutics, Inc. 修饰的毒素
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof
WO2016014428A2 (en) * 2014-07-21 2016-01-28 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
SI3482766T1 (sl) * 2014-08-11 2020-09-30 Delinia, Inc. Spremenjene variante IL-2, ki selektivno aktivirajo regulatorne T celice za zdravljenje avtoimunskih bolezni

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011519882A (ja) 2008-05-08 2011-07-14 アイクリス ゲーエムベーハー ウント コー．カーゲー 自己免疫疾患の治療および／または予防のための薬剤、ならびに制御性ｔ細胞形成のための薬剤
WO2014153111A2 (en) 2013-03-14 2014-09-25 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells
WO2014153063A1 (en) 2013-03-14 2014-09-25 Amgen Inc. AGLYCOSYLATED Fc-CONTAINING POLYPEPTIDES

Also Published As

Publication number Publication date
EP3280725B1 (en) 2020-08-26
JP2023134534A (ja) 2023-09-27
WO2016164937A9 (en) 2018-05-17
WO2016164937A2 (en) 2016-10-13
KR102687530B1 (ko) 2024-07-25
JP2018512151A (ja) 2018-05-17
CN109071623A (zh) 2018-12-21
JP2021153593A (ja) 2021-10-07
KR20250133490A (ko) 2025-09-05
CN115073581A (zh) 2022-09-20
EP3280725A2 (en) 2018-02-14
EP3808764A1 (en) 2021-04-21
NZ736234A (en) 2024-12-20
KR20180133198A (ko) 2018-12-13
CN109071623B (zh) 2022-05-27
WO2016164937A3 (en) 2017-01-12
NZ775714A (en) 2024-12-20
KR20240115933A (ko) 2024-07-26
JP7649349B2 (ja) 2025-03-19

Similar Documents

Publication Publication Date Title
JP7649349B2 (ja) 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質
US11976103B2 (en) Interleukin-2 muteins for the expansion of T-regulatory cells
JP7227951B2 (ja) 制御性ｔ細胞の増殖のためのインターロイキン－２ムテイン
AU2019264645A1 (en) Interleukin-2 muteins for the expansion of T-regulatory cells
EA048640B1 (ru) Мутеины интерлейкина-2 для роста регуляторных т-клеток
BR122021001818B1 (pt) Uso de uma quantidade eficaz de muteína de il-2 humana e de proteína de fusão fc
BR112017021696B1 (pt) Muteína de interleucina-2 humana (il-2) e proteína de fusão-fc
NZ712066B2 (en) Interleukin-2 muteins for the expansion of t-regulatory cells
HK1220695B (en) Aglycosylated fc-containing polypeptides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190426

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200526

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200820

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201110

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210609

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210609

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210616

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210622

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20210820

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20210824

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220412

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20220726

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230126

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20230411

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231108

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240116

R150 Certificate of patent or registration of utility model

Ref document number: 7422480

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150